Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association
Background: Kawasaki disease is an acute vasculitis of childhood that leads to coronary
artery aneurysms in≈ 25% of untreated cases. It has been reported worldwide and is the …
artery aneurysms in≈ 25% of untreated cases. It has been reported worldwide and is the …
European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease–the SHARE initiative
Abstract Objectives The European Single Hub and Access point for paediatric
Rheumatology in Europe initiative aimed to optimize care for children with rheumatic …
Rheumatology in Europe initiative aimed to optimize care for children with rheumatic …
Management of Kawasaki disease
Kawasaki disease (KD) is an acute self-limiting inflammatory disorder, associated with
vasculitis, affecting predominantly medium-sized arteries, particularly the coronary arteries …
vasculitis, affecting predominantly medium-sized arteries, particularly the coronary arteries …
Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study
Background Kawasaki disease is recognized as the most common cause of acquired heart
disease in children in the developed world. Clinical, epidemiologic, and pathologic evidence …
disease in children in the developed world. Clinical, epidemiologic, and pathologic evidence …
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial
AH Tremoulet, S Jain, P Jaggi, S Jimenez-Fernandez… - The Lancet, 2014 - thelancet.com
Background Kawasaki disease, the most common cause of acquired heart disease in
developed countries, is a self-limited vasculitis that is treated with high doses of intravenous …
developed countries, is a self-limited vasculitis that is treated with high doses of intravenous …
Remicade® (infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets and …, 2019 - Taylor & Francis
Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease
Kawasaki disease is a systemic vasculitis of unknown etiology, with clinical observations
suggesting a substantial genetic contribution to disease susceptibility. We conducted a …
suggesting a substantial genetic contribution to disease susceptibility. We conducted a …
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative …
Background Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki
disease, 10–20% of patients have recrudescent fever as a sign of persistent inflammation …
disease, 10–20% of patients have recrudescent fever as a sign of persistent inflammation …
[PDF][PDF] Федеральные клинические рекомендации по оказания медицинской помощи детям с Желчекаменной болезнью
Данные клинические рекомендации подготовлены совместно с Всероссийской
ассоциацией для больных муковисцидозом, рассмотрены и утверждены на заседании …
ассоциацией для больных муковисцидозом, рассмотрены и утверждены на заседании …
Brain injuries from blast
Traumatic brain injury (TBI) from blast produces a number of conundrums. This review
focuses on five fundamental questions including:(1) What are the physical correlates for …
focuses on five fundamental questions including:(1) What are the physical correlates for …